Effect of BMI on efficacy of androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer
{{output}}
BackgroundBody mass index (BMI) has been associated with improved outcomes in several malignancies, including prostate cancer. However, the impact of BMI on treatment efficacy, particularly with androgen receptor pathway inhibitors (ARPIs), in metastatic hormo... ...
